Valion Bio and Shear Kershman Laboratories have completed formulation work for oral mucosal Entolimod, with the next study set to determine whether the needle-free approach can deliver measurable levels of the biologic into the bloodstream.
Key Investor Takeaways
- Valion Bio (NASDAQ:VBIO) has successfully formulated Entolimod using Shear Kershman Laboratories’ BioViscid drug-delivery platform, establishing a potential second development pathway alongside injectable Entolimod.
- The next milestone is a systemic exposure study to determine whether oral mucosal administration produces measurable Entolimod levels in the bloodstream.
- A successful needle-free formulation could potentially broaden deployment options during radiological or nuclear emergencies, although efficacy, safety, stability and regulatory authorization remain to be established.
- Valion estimates the potential U.S. dose opportunity could be approximately 10 to 40 times larger than its injectable program if the oral mucosal product is successfully developed and authorized or approved.
- The company explicitly characterized that estimate as a possible addressable opportunity rather than a revenue forecast, committed purchase volume or demonstrated demand.
Why VBIO Stock Is in Focus
Valion Bio and Shear Kershman Laboratories have completed the formulation stage of a program designed to deliver Entolimod through the lining of the mouth rather than by injection.
The formulation uses SKL’s proprietary BioViscid platform and is intended to enable absorption through the oral mucosa into systemic circulation. The companies will next test whether this approach actually produces measurable systemic exposure to Entolimod and, if successful, characterize its pharmacokinetic profile.
That study represents a critical technical checkpoint. Demonstrating systemic exposure would inform subsequent formulation optimization, dosing and further development work.
The oral mucosal program is being developed alongside, rather than as a replacement for, Valion’s injectable Entolimod program. Entolimod is an investigational biologic being developed as a potential medical countermeasure for acute radiation syndrome.
Why This Matters for Investors
The formulation milestone expands Entolimod’s development strategy, but it does not yet demonstrate that the needle-free version can deliver therapeutically relevant levels of the drug or provide protection from radiation exposure.
The potential strategic value rests on whether oral mucosal delivery can eventually simplify distribution and administration. Valion is exploring whether the approach could reduce reliance on injections and trained personnel while potentially improving storage and transportation characteristics.
If those objectives are achieved, the company believes Entolimod could be evaluated for distribution to military and emergency-response personnel before potential radiation exposure, creating a different preparedness model from treatment administered only after an incident.
Valion estimates that such an approach could create a U.S. dose opportunity approximately 10 to 40 times the size of its injectable program, based on supplying specified military, firefighter and law-enforcement populations. That figure remains highly conditional and depends on product performance, regulatory decisions, government procurement priorities and funding.
The distinction is important for the valuation narrative: the formulation work introduces a potentially broader use case, while the evidence needed to establish that opportunity has yet to be generated.
What to Watch Next
The most immediate catalyst is the systemic exposure study. Measurable absorption would allow Valion and SKL to move toward pharmacokinetic characterization, formulation optimization and dosing work.
Beyond that, investors can watch for stability, safety and efficacy data, including whether the formulation could reduce refrigeration requirements. Regulatory progress and any evidence supporting broader preparedness applications will ultimately determine whether the needle-free program develops into a meaningful second pathway for Entolimod.